V-set and transmembrane domain containing 2 likeGenealiases: C20orf102 · dJ1118M15.2
Q-omics provides the consensus-scored VSTM2L profile across patient tissues and cancer cell-line models. VSTM2L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VSTM2L is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, VSTM2L RNA expression shows 17,168 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where VSTM2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSTM2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSTM2L survival associations across molecular data types. VSTM2L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSTM2L RNA expression–survival associations across cancer types. High VSTM2L expression shows unfavorable associations in BLCA, UCEC, OV, STAD and LUSC, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for VSTM2L RNA expression.
This table summarizes VSTM2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VSTM2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSTM2L shows lower tumor expression in LUSC and READ and higher tumor expression in THCA, LUAD, BRCA and KIRP. The THCA box plot shows higher VSTM2L RNA expression in tumor versus normal tissue (log2 FC = +2.334, t-test p < 0.001).
This table shows molecular features associated with VSTM2L in patient tissues and cancer cell lines. In patient samples, VSTM2L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VSTM2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
